此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

将 Certolizumab 添加到化疗 + Nivolumab 治疗可通过手术治疗的肺癌患者

2026年9月29日 更新者:Memorial Sloan Kettering Cancer Center

新辅助 Nivolumab + 铂类化疗 + Certolizumab 在可切除 II-III 期肺癌患者中的 2 期试验

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Paul Paik, MD
  • 电话号码:646-608-3759
  • 邮箱:paikp@mskcc.org

研究联系人备份

  • 姓名:Matthew Bott, MD
  • 电话号码:212-639-5944
  • 邮箱:bottm@mskcc.org

学习地点

    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759
      • Uniondale、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • 接触:
          • Paul Paik, MD
          • 电话号码:646-608-3759

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Untreated stage II-III (AJCC 8th edition) non-small cell lung cancers with operable and resectable disease determined by a thoracic surgeon

  • Histologic confirmation of disease at MSKCC

  • Age 18 years or older

  • Karnofsky Performance Status ≥ 70

  • Adequate bone marrow, liver and renal function, as specified below:

    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9 /L
    • Lymphocyte count ≥0.5 x10^9/L (500/µL)
    • Hemoglobin ≥ 9 g/dL
    • Platelets ≥ 100 x 10^9 /L
    • Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
    • AST and ALT ≤ 2.5 x ULN
    • Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
    • Serum albumin ≥25 g/L (2.5 g/dL)
    • For patients not receiving therapeutic anticoagulation: INR or aPTT ≤1.5 x ULN
    • For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
  • Negative PPD test or interferon-gamma release assay (including but not limited to QuantiFERON-TB Gold)

  • For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment

  • Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 5 months thereafter

  • Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1

  • Ability to provide written, informed consent. Legally Authorized Representatives are permitted.

  • Negative HIV test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ³ 200/µL, and have an undetectable viral load

  • Negative hepatitis B surface antigen (HBsAg) test at screening Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. Note: The HBV DNA test will be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.

  • Patient with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Exclusion Criteria:

  • Presence of an FDA approved targeted therapy for patients with NSCLC harboring a genomic aberration for which an FDA-approved targeted therapy is indicated
  • Hypersensitivity to platinum agents
  • Prior use of TNF-α inhibitor
  • Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment

Note: this exclusion criteria has the following excpetions:

  • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.

  • Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

  • Topical steroids

    • Active or history of autoimmune disease or immune deficiency
    • Active or history of autoimmune disease or immune deficiency including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, antiphospholipid antibody syndrome Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis.

Note: This exclusion criteria has the following exceptions:

  1. Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.

  2. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.

  3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

    • Rash must cover < 10% of body surface area

    • Disease is well controlled at baseline and requires only low-potency topical corticosteroids

    • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months

      • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
      • Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher) applicable only for cisplatin therapy.
      • Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush
      • Active tuberculosis or untreated, latent tuberculosis Note: If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.
      • Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, or cerebrovascular accident) within 3 months prior to initiation of study treatment, or unstable arrhythmia Note: Patients are ineligible if they have a history of myocardial infarction or
      • Unstable angina within the past 12 months
      • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
      • Acute or chronic Hepatitis B or C infection
      • Known HIV infection requiring antiretroviral medications and those with AIDS
      • Active herpes zoster infection
      • Current treatment with anti-viral therapy for HBV
      • Non-healed infected skin ulcers
      • Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5mmol/L, calcium > 12mg/dL or corrected serum calcium > ULN)
      • Prior history of other malignancy with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, Stage I uterine cancer, localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast
      • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
      • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
      • Prior allogeneic stem cell or solid organ transplantation
      • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
      • Live, attenuated vaccines (e.g., FluMist) are prohibited within 4 weeks prior to initiation of study treatment, during treatment with nivolumab, and for 5 months after the last dose of nivolumab.
      • Treatment with investigational therapy within 28 days prior to initiation of study treatment
      • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
      • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
      • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
      • Known hypersensitivity to Chinese hamster ovary cell products or to any component of the nivolumab formulation
      • Known allergy or hypersensitivity to any component of the Certolizumab pegol formulation
      • Known allergy or hypersensitivity to any component of the platinum-based chemotherapy formulations
      • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of nivolumab, within 3 months after the final dose of Certolizumab pegol, and within 6 months after the final dose of carboplatin, cisplatin, pemetrexed or gemcitabine treatment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Participants with resectable stage II-III lung cancers (Adenocarcinoma)

This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle

Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.

Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.

Patients with lung adenocarcinoma

实验性的:Participants with resectable stage II-III lung cancers (squamous cell carcinoma)

This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + nivolumab + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle

Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.

Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.

Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Participants complete pathologic response (CPR)
大体时间:up to 2 years

To evaluate the complete pathologic response (CPR) of participants with stage II-III lung cancers who receive treatment with neoadjuvant platinum-based chemotherapy + certolizumab pegol. Major pathologic response (MPR) is defined as 10% or less residual viable tumor after neoadjuvant therapy

up to 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Paul Paik, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月19日

初级完成 (估计的)

2026年10月1日

研究完成 (估计的)

2026年10月1日

研究注册日期

首次提交

2021年7月27日

首先提交符合 QC 标准的

2021年7月27日

首次发布 (实际的)

2021年8月5日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅